DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quinaretic (Quinapril Hydrochloride / Hydrochlorothiazide) - Summary

 
 



BOXED WARNING

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, QUINARETIC should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

QUINARETIC SUMMARY

QUINARETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.

QUINARETIC is indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).

In using QUINARETIC, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).

Angioedema in Black Patients:

Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.


See all Quinaretic indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Quinaretic (Quinapril / Hydrochlorothiazide)

Research suggests team-based care is most effective way to control hypertension
Source: Hypertension News From Medical News Today [2014.10.24]
Patients diagnosed with high blood pressure are given better control of their condition from a physician-pharmacist collaborative intervention than physician management alone, according to new...

Exalenz Bioscience launches pivotal study of world's first breath-based test to diagnose clinically significant portal hypertension
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.10.23]
Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced the start of a pivotal...

Binge drinking in young men linked with increased risk of hypertension
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2014.10.21]
Binge drinking in early adulthood is associated with an increased likelihood of high blood pressure in males, while low to moderate alcohol use in early adulthood is associated with a decreased...

Uncontrolled hypertension highest among patients with moderate-to-severe psoriasis
Source: Hypertension News From Medical News Today [2014.10.20]
Patients with moderate and severe psoriasis have the greatest likelihood of uncontrolled hypertension compared to patients without psoriasis.

UF researchers use plants to study new ways of delivering drugs for pulmonary hypertension
Source: Endocrinology News From Medical News Today [2014.10.17]
UF researchers are using the leaves of plants to study new ways to deliver drugs that treat pulmonary hypertension, a disease with few treatment options, according to a study published online in...

more news >>

Clinical Trials Related to Quinaretic (Quinapril / Hydrochlorothiazide)

Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF [Recruiting]
Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this. The primary outcome will be time to recurrent AF.

more trials >>


Page last updated: 2014-10-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014